Athena Athena

X
[{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$3,881.0 million\u202c","upfrontCash":"$16.0 million","newsHeadline":"Alteogen Enters into a Global License Agreement with a Top Ten Pharma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Alteogen"},{"orgOrder":0,"company":"Alteogen","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","amount":"$109.0 million","upfrontCash":"$6.0 million","newsHeadline":"Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products Enabled Hybrozyme\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SOUTH KOREA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Alteogen"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Scripps Research","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bridge Biotherapeutics and Scripps Research Launch Research Collaboration to Develop Discovery Platform and Novel Covalent Probes Based on Chemical Biology and Chemoproteomics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"SOUTH KOREA","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Bridge Biotherapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the multi-year collaboration agreement, Scripps will conduct research and development activities, and Bridge Biotherapeutics will retain an exclusive option to acquire worldwide license and patent rights from the research program.

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Scripps Research

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 08, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Alteogen has granted worldwide rights, except for a few Asian countries, for Intas to develop two products in combination with ALT-B4.

            Lead Product(s): ALT-B4,Undisclosed

            Therapeutic Area: Oncology Product Name: ALT-B4

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Intas Pharmaceuticals

            Deal Size: $109.0 million Upfront Cash: $6.0 million

            Deal Type: Collaboration January 07, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, Alteogen has granted worldwide rights for TTPC to develop multiple products in combination with ALT-B4.

            Lead Product(s): ALT-B4

            Therapeutic Area: Oncology Product Name: ALT-B4

            Highest Development Status: Discovery Platform Product Type: Large molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $3,881.0 million‬ Upfront Cash: $16.0 million

            Deal Type: Licensing Agreement June 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY